Search

Obesity is associated with a number of metabolic disorders that lead to the development of type 2 diabetes, hyperlipidemia and ultimately cardiovascular diseases. An important role in the pathogenesis of metabolic disorders accompanying obesity is probably played by the alterations of adipose tissue characteristics: metabolic, endocrine and immune functions. The key component of obesity treatment, the weight-reduction energy-restricted diet, leads not only to the reduction of weight (specifically fat mass), but also to correction of obesity accompanying metabolic disorders. The mechanisms which mediate the metabolic effect of the weight-reduction energy-restricted diet, are unclear. It can be assumed that the weight-reduction diet "corrects" the impaired functions of the obese individuals adipose tissue and, subsequently, of the resulting metabolic disorders. The following text presents an overview of the changes of morphological and functional characteristics of adipose tissue that are induced by weight-reduction energy-restricted diets in obese individuals: the energy-restricted diet and the associated weight reduction cause a change in the size and differentiation of adipocytes, a change of metabolic functions, primarily of the regulation of adipose tissue lipolysis and lipogenesis, change in the regulation of endocrine functions and, finally, they lead to the change in the immune function indicators, i.e. adipose tissue infiltration with immune cells and secretion of a spectrum of cytokines. The knowledge about the mechanisms of favourable metabolic effects of energy-restricted diets may lead to an advancement in non-pharmacological procedures of therapy for obesity and its complications, and, in the longer, term to the development of new therapeutic pharmacological procedures.Key words: energy-restricted diet - obesity - weight reduction - adipose tissue.

Unlabelled: The objective of our study was to determine a correlation between the level of adipocyte fatty acid-binding protein (A-FABP) (as a possible link between metabolic syndrome and atherosclerosis), the calcium score (CS) and laboratory parameters, including insulin resistance indices in asymptomatic first degree relatives of patients with cardiovascular diseases. SET AND METHODOLOGY: Examination was conducted in 82 persons (53 male) with the average age of 52.79 ± 9.6. The examinations consisted of anthropometric and physical tests (determination of body weight, height, body mass index - BMI and casual blood pressure measurement), laboratory analysis (uric acid, creatinine, lipid panel, insulin, glucose, C-reactive protein, fibrinogen, glycated hemoglobin, adipocyte fatty acid-binding protein - A-FABP) and determination of insulin resistance indices HOMA and QUICKI. Total calcium score (CS) was determined by the Agatston method without the need to administer a contrast agent., Results: The value of the A-FABP level does not show a statistically significant dependence on the categorised CS or on non-categorised CS values. There is a statistically significant positive dependence of the level of A-FABP on the HOMA index (p = 0.00688) and a statistically significant negative dependence on the QUICKI index (p = 0.0068). The A-FABP level is statistically significantly higher in women (p = 0.048), in elder persons (p = 0.043), and in persons with higher BMI values (p = 0.029). Among continuous variables, statistically significant is the difference in the A-FABP level in relation to age (p = 0.002), creatinine (p = 0.026), insulin (p = 0.005), and BMI (p = 0.031)., Conclusion: Our study confirmed the correlation of the A-FABP level with insulin resistance indices, BMI, age, gender, and insulin and creatinine levels in a group of asymptomatic first degree relatives of patients with cardiovascular diseases. A-FABP could potentially be a marker when determining the risk of CVD; however, this conclusion requires additional clinical trials.

Unlabelled: Endocrinal products of adipocytes (PPARgamma, A-FABP, E-FABP, leptin, adiponectin and others) modulate insulin tissue sensitivity enabling them to participate in the ethiopathogenesis of diabetes mellitus type 2 (DM2T). Persons with DM2T are characterised by typical changes in lipid spectrum (lower HDL-cholesterol and higherTAG) and in the endocrinal function of subcutaneous adipose tissue; adipocytes produce more PPARgamma, A-FABP and E-FABP and less adiponectin., Aims of the Study: To measure chosen markers of metabolic syndrome (MS) in serum and in abdominal subcutaneous adipose tissue in healthy persons and patients with DMT2, to determine basic statistical characteristics of investigated parameters and to discus their role in the genesis and progress of the MS., Methods: Samples of blood and abdominal subcutaneous adipose tissue were collected from each participant (healthy: 7 men and 8 women; diabetics: 18 men, 11 women) to investigate the levels of HDL, TAG, insulin, C-peptide, glycaemia and the concentrations of A-FABP, E-FABP, leptin, adiponectin, resistin, PPARgamma and TNFalpha., Results: In most cases the average concentration of investigated parameters in serum was higher in persons with DM 2 regardless of gender. Lower values were only found for HDL and adiponectin. The same situation prevailed in the subcutaneous adipose tissue. Values of most other parameters (A-FABP, E-FABP, and PPARgamma) were also higher in patients. The values of measured parameters not only differed in healthy and in sick persons but depended on gender. The increase/decrease in concrete parameters was greater in diabetic women than diabetic men., Conclusion: Higher concentrations of A-FABP, E-FABP in serum and in subcutaneous adipose tissue in diabetic persons also higher concentrations of PPARgamma in subcutaneous adipose tissue suggest that these investigated parameters are closely associated with obesity and MS. We can assume that in the near future these parameters will be used in clinical work for diagnosis of this syndrome.